Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Anti-neuropathic Pain Mechanistic Study on A. conyzoides Essential Oil, Precocene II, Caryophyllene, or Longifolene as Single Agents and in Combination with Pregabalin

Author(s): Y. Purwandi Sukmawan, Kusnandar Anggadiredja and I. Ketut Adnyana*

Volume 22, Issue 6, 2023

Published on: 27 July, 2022

Page: [924 - 931] Pages: 8

DOI: 10.2174/1871527321666220418121329

open access plus

conference banner
Abstract

Background: Neuropathic pain has become a contributor to the global burden of illness. However, the currently available drugs exhibit inadequate pain relief and significant side effects. Our previous study demonstrated that the essential oil of Ageratum conyzoides exerts potent antineuropathic pain activity through opioid receptor activation. Precocene II, longifolene, and caryophyllene are the largest component of the A. conyzoides essential oil.

Objective: The objective of the study was to determine the anti-neuropathic pain activity of precocene II, longifolene, and caryophyllene as single agents and in combination with pregabalin. Possible mechanisms of action involving the opioid receptor, ATP-sensitive potassium channel, and gammaaminobutyric acid (GABA) were further investigated.

Methods: The experimental animals (male mice Swiss Webster) were divided randomly into seven groups, namely, Normal control (naïve mice), Negative control (CMC 1%), Sham (CMC 1%), Positive control (Pregabalin 0,195 mg/ 20 g BW of mice), Test I (Precocene II 21.09 mg/Kg BW), Test II (Longifolene 9.94 mg/Kg BW), and Test III (Caryophyllene 3.64 mg/Kg BW). Each group contained 3 animals. The test groups that demonstrated anti-neuropathic pain activity were further tested in combination with pregabalin, followed by mechanistic studies. The negative, positive, and test I-III groups were induced with chronic constriction injury.

Results: The results of the study demonstrated that caryophyllene and longifolene, but not precocene II, exerted anti-neuropathic pain activity. The caryophyllene was shown to involve in the activation of opioid receptors and ATP-sensitive potassium channels. It was also reported to increase GABA concentration in the spinal cord. We further found that longifolene exerted its action via opioid receptor activation. The combination of A. conyzoides essential oil, longifolene, or caryophyllene with pregabalin demonstrated additive anti-neuropathic pain activity.

Conclusion: Taken together, the results of the present study suggested that the A. conyzoides essential oil and caryophyllene have the potential to be developed as novel drugs to treat neuropathic pain.

Keywords: A. conyzoides, caryophyllene, essential oil, longifolene, precocene II, neuropathic pain.

« Previous Next »
Graphical Abstract

[1]
Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers 2017; 3(1): 17002.
[http://dx.doi.org/10.1038/nrdp.2017.2] [PMID: 28205574]
[2]
Murnion BP. Neuropathic pain: Current definition and review of drug treatment. Aust Prescr 2018; 41(3): 60-3.
[http://dx.doi.org/10.18773/austprescr.2018.022] [PMID: 29921999]
[3]
Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: A systematic review and meta-analysis of population studies. BMJ Open 2016; 6(6): e010364.
[http://dx.doi.org/10.1136/bmjopen-2015-010364] [PMID: 27324708]
[4]
Basić-Kes V, Zavoreo I, Bosnar-Puretić M, et al. Neuropathic pain. Acta Clin Croat 2009; 48(3): 359-65.
[PMID: 20055264]
[5]
McCarberg B, D’Arcy Y, Parsons B, Sadosky A, Thorpe A, Behar R. Neuropathic pain: A narrative review of etiology, assessment, diagnosis, and treatment for primary care providers. Curr Med Res Opin 2017; 33(8): 1361-9.
[http://dx.doi.org/10.1080/03007995.2017.1321532] [PMID: 28422517]
[6]
Wang Y, Yang H, Shen C, Luo J. Morphine and pregabalin in the treatment of neuropathic pain. Exp Ther Med 2017; 13(4): 1393-7.
[http://dx.doi.org/10.3892/etm.2017.4102] [PMID: 28413483]
[7]
Mehta M, Shah J, Khakhkhar T, Shah R, Hemavathi KG. Anticonvulsant hypersensitivity syndrome associated with carbamazepine administration: Case series. J Pharmacol Pharmacother 2014; 5(1): 59-62.
[http://dx.doi.org/10.4103/0976-500X.124428] [PMID: 24554914]
[8]
Ono Y, Shimo T, Shirafuji Y, et al. Drug-induced hypersensitivity syndrome caused by carbamazepine used for the treatment of trigeminal neuralgia. Case Rep Dent 2016; 2016: 4605231.
[http://dx.doi.org/10.1155/2016/4605231] [PMID: 27885344]
[9]
Cruccu G, Truini A. A review of neuropathic pain: From guidelines to clinical practice. Pain Ther 2017; 6 (Suppl. 1): 35-42.
[http://dx.doi.org/10.1007/s40122-017-0087-0] [PMID: 29178033]
[10]
Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. The Cochrane Database Syst Rev 2019; 1: CD007076.
[http://dx.doi.org/10.1002/14651858.CD007076.pub3]
[11]
Sukmawan YP, Anggadiredja K, Adnyana IK. Anti-neuropathic pain activity of Ageratum conyzoides L due to the essential oil components. CNCNDDT 2021; 20(2): 181-9.
[http://dx.doi.org/10.2174/1871527319666201120144228] [PMID: 33222681]
[12]
National Research Council (US). Guide for the Care and Use of Laboratory Animals. 8th Ed.; Washington, DC: National Academies Press (US) 2011.
[13]
Yalcin I, Megat S, Barthas F, et al. The sciatic nerve cuffing model of neuropathic pain in mice. J Vis Exp 2014; 89(89): 51608.
[http://dx.doi.org/10.3791/51608] [PMID: 25078668]
[14]
Kaur G, Jaggi AS, Singh N. Exploring the potential effect of Ocimum sanctum in vincristine-induced neuropathic pain in rats. J Brachial Plex Peripher Nerve Inj 2010; 5: 3.
[PMID: 20181005]
[15]
Rafieian-Kopaei M, Shakiba A, Sedighi M, Bahmani M. The analgesic and anti-inflammatory activity of Linum usitatissimum in Balb/c mice. J Evid Based Complementary Altern Med 2017; 22(4): 892-6.
[http://dx.doi.org/10.1177/2156587217717416] [PMID: 28750553]
[16]
Hylden JL, Wilcox GL. Intrathecal morphine in mice: A new technique. Eur J Pharmacol 1980; 67(2-3): 313-6.
[http://dx.doi.org/10.1016/0014-2999(80)90515-4] [PMID: 6893963]
[17]
Wallin J, Cui JG, Yakhnitsa V, Schechtmann G, Meyerson BA, Linderoth B. Gabapentin and pregabalin suppress tactile allodynia and potentiate spinal cord stimulation in a model of neuropathy. Eur J Pain 2002; 6(4): 261-72.
[http://dx.doi.org/10.1053/eujp.2002.0329] [PMID: 12161092]
[18]
Adamus G, Manczak M, Machnicki M. Expression of CC chemokines and their receptors in the eye in autoimmune anterior uveitis associated with EAE. Invest Ophthalmol Vis Sci 2001; 42(12): 2894-903.
[PMID: 11687534]
[19]
Vranken JH. Mechanisms and treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem 2009; 9(1): 71-8.
[http://dx.doi.org/10.2174/187152409787601932] [PMID: 20021340]
[20]
Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003; 63(1): 17-32.
[http://dx.doi.org/10.2165/00003495-200363010-00002] [PMID: 12487620]
[21]
Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008; 11(2): S133-53.
[http://dx.doi.org/10.36076/ppj.2008/11/S133] [PMID: 18443637]
[22]
Wang YH, Sun JF, Tao YM, Chi ZQ, Liu JG. The role of kappa-opioid receptor activation in mediating antinociception and addiction. Acta Pharmacol Sin 2010; 31(9): 1065-70.
[http://dx.doi.org/10.1038/aps.2010.138] [PMID: 20729876]
[23]
Wu XF, Liu WT, Liu YP, Huang ZJ, Zhang YK, Song XJ. Reopening of ATP-sensitive potassium channels reduces neuropathic pain and regulates astroglial gap junctions in the rat spinal cord. Pain 2011; 152(11): 2605-15.
[http://dx.doi.org/10.1016/j.pain.2011.08.003] [PMID: 21907492]
[24]
Tsantoulas C, McMahon SB. Opening paths to novel analgesics: The role of potassium channels in chronic pain. Trends Neurosci 2014; 37(3): 146-58.
[http://dx.doi.org/10.1016/j.tins.2013.12.002] [PMID: 24461875]
[25]
Simard JM, Woo SK, Schwartzbauer GT, Gerzanich V. Sulfonylurea receptor 1 in central nervous system injury: A focused review. J Cereb Blood Flow Metab 2012; 32(9): 1699-717.
[http://dx.doi.org/10.1038/jcbfm.2012.91] [PMID: 22714048]
[26]
Zhu X, Liu J, Gao Y, Cao S, Shen S. ATP-sensitive potassium channels alleviate postoperative pain through JNK-dependent MCP-1 expression in spinal cord. Int J Mol Med 2015; 35(5): 1257-65.
[http://dx.doi.org/10.3892/ijmm.2015.2143] [PMID: 25812598]
[27]
Ocaña M, Cendán CM, Cobos EJ, Entrena JM, Baeyens JM. Potassium channels and pain: Present realities and future opportunities. Eur J Pharmacol 2004; 500(1-3): 203-19.
[http://dx.doi.org/10.1016/j.ejphar.2004.07.026] [PMID: 15464034]
[28]
Li C, Lei Y, Tian Y, et al. The etiological contribution of GABAergic plasticity to the pathogenesis of neuropathic pain. Mol Pain 2019; 15: 1744806919847366.
[http://dx.doi.org/10.1177/1744806919847366] [PMID: 30977423]
[29]
Todd AJ. Neuronal circuitry for pain processing in the dorsal horn. Nat Rev Neurosci 2010; 11(12): 823-36.
[http://dx.doi.org/10.1038/nrn2947] [PMID: 21068766]
[30]
Fu H, Li F, Thomas S, Yang Z. Hyperbaric oxygenation alleviates chronic constriction injury (CCI)-induced neuropathic pain and inhibits GABAergic neuron apoptosis in the spinal cord. Scand J Pain 2017; 17(17): 330-8.
[http://dx.doi.org/10.1016/j.sjpain.2017.08.014] [PMID: 28927648]
[31]
Campo-Soria C, Chang Y, Weiss DS. Mechanism of action of benzodiazepines on GABAA receptors. Br J Pharmacol 2006; 148(7): 984-90.
[http://dx.doi.org/10.1038/sj.bjp.0706796] [PMID: 16783415]

Rights & Permissions Print Cite
Article Metrics
4
© 2024 Bentham Science Publishers | Privacy Policy